SEC Tracker
Get the app

Vivos Therapeutics VVOS

Vivos Therapeutics acquires SOD assets

Item 1.01 Enters material agreement, Item 2.01 Completes acquisition or sale, Item 3.02 Unregistered share sale

Form
8-K
Filed
Importance
Major
  1. Acquired 11% of SOD's shares
  2. Received 50% co-ownership of pseudohypoxia test IP
  3. Issued 12,000 Series C Preferred shares
  4. No cash exchanged in transaction

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Vivos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Positron POSC public float $22M, Jun 30, 2025
  2. United Health Products UEEC public float $25M, Jun 30, 2025
  3. Allurion Technologies ALUR public float $21M, Jun 30, 2025
  4. Neuroone Medical Technologies NMTC public float $26M, Mar 31, 2025, over 18 months old
  5. Precision Optics POCI public float $26M, Dec 31, 2025